Global Patent Index - EP 3652338 A1

EP 3652338 A1 20200520 - METHOD FOR PREDICTING RESPONSIVENESS TO IMMUNOTHERAPY

Title (en)

METHOD FOR PREDICTING RESPONSIVENESS TO IMMUNOTHERAPY

Title (de)

VERFAHREN ZUR VORHERSAGE DER ANSPRECHBARKEIT AUF EINE IMMUNTHERAPIE

Title (fr)

MÉTHODE DE PRÉDICTION DE LA SENSIBILITÉ À UNE IMMUNOTHÉRAPIE

Publication

EP 3652338 A1 20200520 (EN)

Application

EP 18745848 A 20180713

Priority

  • EP 17181531 A 20170714
  • EP 2018069080 W 20180713

Abstract (en)

[origin: WO2019012105A1] This invention relates to the field of cancer diagnostics and therapeutics. In particular, the invention relates to a method for predicting responsiveness to immunotherapy in a subject having a neoplastic disease, the method comprising: (A) determining the methylation level of a gene or a fragment thereof selected from the group consisting of internexin neuronal intermediate filament protein alpha (ΓΝΑ), protein tyrosine phosphatase, receptor type C-associated protein (PTPRCAP), semaphorin 3B (SEMA3B), kelch-like family member 6 (KLHL6), and Ras association domain family member 1 (RASSF1) in a sample from the subject, wherein: hypomethylation of the gene or fragment thereof in the sample indicates that the subject will be responsive to immunotherapy; or hypermethylation of the gene or fragment thereof in the sample indicates that the subject will be unresponsive to immunotherapy; or (B) (i) determining a methylation profile of two or more genes or fragments thereof selected from the group consisting of IN A, PTPRCAP, SEMA3B, KLHL6, and RASSF1 in the sample from the subject; (ii) comparing the methylation profile as determined in (i) with a reference methylation profile, said reference methylation profile representing a known responsiveness to immunotherapy; (iii) finding a deviation or no deviation of the methylation profile as determined in (i) from said reference methylation profile; and (iv) attributing said finding of deviation or no deviation to a particular prediction of responsiveness of the subject to immunotherapy.

IPC 8 full level

C12Q 1/68 (2018.01); C12Q 1/6886 (2018.01)

CPC (source: EP)

C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/154 (2013.01)

Citation (search report)

See references of WO 2019012105A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2019012105 A1 20190117; EP 3652338 A1 20200520

DOCDB simple family (application)

EP 2018069080 W 20180713; EP 18745848 A 20180713